In this week’s episode of “The Readout LOUD,” the biotech podcast from STAT, we explore the potential impacts of the Trump presidency on the FDA, the biotech industry, and the stock market. To delve into these important topics, we have invited three guests: Lizzy Lawrence, who covers the FDA for STAT, Baird analyst Brian Skorney, and biotech executive Daphne Zohar.
One key question that arises is whether the reduced regulation by the FDA under the Trump administration will benefit the biotech industry. With fewer regulatory hurdles, will biotech companies be able to bring new drugs and treatments to market more quickly? This is a topic that our guests will discuss in detail.
Another area of concern is the impact on vaccine makers like Pfizer. With the spotlight on healthcare and pharmaceuticals during the pandemic, will these companies face increased scrutiny or challenges in the coming years? The discussion will shed light on the potential risks and opportunities for vaccine manufacturers in the current political climate.
Additionally, we will explore the “Make America Healthy Again” movement led by Robert F. Kennedy Jr. How will this movement influence the obesity drug market, and what implications does it have for the broader biopharma industry? Our guests will share their insights and analysis on these important issues.
For more in-depth analysis on what Trump’s second term could mean for the FDA, key figures in the MAHA movement, and reactions from leaders in the biopharma industry following the election, be sure to check out the links provided in the article. You can also listen to “The Readout LOUD” on Apple Podcasts, Spotify, TuneIn, or wherever you prefer to get your podcasts.
In addition to our guests, Adam Feuerstein, a senior writer and biotech columnist at STAT, brings a wealth of knowledge and expertise to the discussion. As a co-host of the podcast and author of the newsletter Adam’s Biotech Scorecard, he offers valuable insights on the intersection of drug development, business, and biotechnology.
Allison DeAngelis, the East Coast biotech and venture capital reporter at STAT, provides a unique perspective on where scientific ideas and money intersect in the biotech industry. As a co-host of “The Readout LOUD,” she brings her expertise to the table to enrich the conversation.
Elaine Chen, the national biotech reporter at STAT, co-writes The Readout newsletter and co-hosts the weekly biotech podcast. Her coverage of the biotech sector and contributions to the podcast offer a comprehensive view of the latest developments and trends in the industry.
Overall, this week’s episode of “The Readout LOUD” promises to be a stimulating and informative discussion on the implications of the Trump presidency on the FDA, the biotech industry, and the stock market. Stay tuned for valuable insights and analysis from our expert guests and hosts.
